US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

crane

190.84

+0.84000.44%

Volume:165.46K

Turnover:31.48M

Market Cap:10.98B

PE:31.72

High:191.10

Open:188.28

Low:188.28

Close:190.00

52wk High:203.89

52wk Low:127.04

Shares:57.55M

Float Shares:48.77M

Volume Ratio:1.65

T/O Rate:0.34%

Dividend:0.87

Dividend Rate:0.46%

EPS(TTM):6.02

EPS(LYR):5.15

ROE:17.94%

ROA:9.25%

PB:5.82

PE(LYR):37.04

Loading ...

Overview Company News Filings

CR Construction Group Holdings Full Year 2024 Earnings: EPS: HK$0.11 (vs HK$0.14 in FY 2023)

Simply Wall St.

BioInvent’s anti-TNFR2 antibody BI-1808 showcased at the 16th Annual T-Cell Lymphoma Forum

ACCESS Newswire

Press Release: SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

Aptevo Therapeutics Says Two Additional Patients In Early-Stage Leukemia Trial Achieve Remission Within 30 Days of Treatment

RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment

ACCESS Newswire

CR Construction Group Announces Final Dividend for 2024

BioInvent Receives FDA Orphan Drug Designation for BI-1808 for the Treatment of T-cell Lymphoma

ACCESS Newswire

CR Double-Crane Pharmaceutical 2024 Profit Down 3%; Shares Decline 3%

MT Newswires Live

Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical Data in 2H:2025

CR Double-Crane Reports 2024 Financial Results with Dividend Proposal

Kratos Defense begins building IPIF in Crane, Indiana to support MACH-TB

Press Release: INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA® and OPDIVO®

Crane Company (CR): Among the Best Reddit Stocks to Invest In

Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia

INAB: Introducing INB-600, A γδ T Cell Engager Platform

Zacks Small Cap Research

Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

3 Industrials Stocks Walking a Fine Line

CR Sanjiu Logs 18% Boost in 2024 Profit

MT Newswires Live

The Agfa-Gevaert Group in 2024: strong performance from growth engines offsets decline in traditional film markets - regulated information

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CR/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CR\",,,,,undefined,":{"symbol":"CR","market":"US","secType":"STK","nameCN":"crane","latestPrice":190.84,"timestamp":1755790767488,"preClose":190,"halted":0,"volume":165456,"delay":0,"floatShares":48765462,"shares":57546840,"eps":6.016852,"marketStatus":"Trading","change":0.84,"latestTime":"08-21 11:39:48 EDT","open":188.2801,"high":191.095,"low":188.2801,"amount":31482793.9512,"amplitude":0.014815,"askPrice":191.11,"askSize":2,"bidPrice":190.45,"bidSize":17,"shortable":3,"etf":0,"ttmEps":6.016852,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1755806400000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":190,"dividendRate":0.004559,"postHourTrading":{"tag":"盘后","latestPrice":190,"preClose":190,"latestTime":"16:36 EDT","volume":73348,"amount":13936120,"timestamp":1755722210232},"volumeRatio":1.652214,"impliedVol":0.2556,"impliedVolPercentile":0.032},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CR\",,,,,undefined,":{"symbol":"CR","floatShares":48765462,"roa":"9.25%","roe":"17.94%","lyrEps":5.152097,"volumeRatio":1.652214,"shares":57546840,"dividePrice":0.87,"high":191.095,"amplitude":0.014815,"preClose":190,"low":188.2801,"week52Low":127.04,"pbRate":"5.82","psRate":"4.93","week52High":203.89,"institutionHeld":0.6875,"latestPrice":190.84,"committee":0.789474,"eps":6.016852,"divideRate":0.004559,"volume":165456,"delay":0,"ttmEps":6.016852,"open":188.2801,"prevYearClose":151.75,"prevWeekClose":189.19,"prevMonthClose":195.77,"prevQuarterClose":189.89,"fiveDayClose":190.98,"twentyDayClose":189.17,"sixtyDayClose":174.13},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CR\",params:#limit:5,,,undefined,":[{"date":"2025-08-29","symbol":"CR","amount":0.23,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-08-29","defaultRemindTime":1756474200000,"name":"crane","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-10","payableDate":"2025-08-29","currency":"USD","dateTimestamp":1756440000000,"payDate":"2025-09-10"},{"market":"US","date":"2025-07-28","symbol":"CR","fiscalQuarterEnding":"2025/06","expectedEps":1.34,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1753675200000,"reportTimeType":"post","actualEps":1.49},{"date":"2025-05-30","symbol":"CR","amount":0.23,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-30","defaultRemindTime":1748611800000,"name":"crane","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-11","payableDate":"2025-05-30","currency":"USD","dateTimestamp":1748577600000,"payDate":"2025-06-11"},{"market":"US","date":"2025-04-28","symbol":"CR","fiscalQuarterEnding":"2025/03","expectedEps":1.29,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1745812800000,"reportTimeType":"post","actualEps":1.39},{"date":"2025-02-28","symbol":"CR","amount":0.23,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-28","defaultRemindTime":1740753000000,"name":"crane","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-12","payableDate":"2025-02-28","currency":"USD","dateTimestamp":1740718800000,"payDate":"2025-03-12"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CR\",market:\"US\",,,undefined,":[{"executeDate":"2017-02-24","recordDate":"2017-02-28","paymentDate":"2017-03-09","value":0.33,"currency":"USD"},{"executeDate":"2017-05-26","recordDate":"2017-05-31","paymentDate":"2017-06-09","value":0.33,"currency":"USD"},{"executeDate":"2017-08-29","recordDate":"2017-08-31","paymentDate":"2017-09-08","value":0.33,"currency":"USD"},{"executeDate":"2017-11-29","recordDate":"2017-11-30","paymentDate":"2017-12-08","value":0.33,"currency":"USD"},{"executeDate":"2018-02-27","recordDate":"2018-02-28","paymentDate":"2018-03-09","value":0.35,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1111,"buy":0.7778,"hold":0.1111,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7778,"analysts":9,"updateTime":1745985600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CR","date":"2025-08-20","current":31.405395,"percent":0.722313,"low":8.74154,"twenty":14.045193,"median":24.891934,"eighty":34.721243,"high":224.415426,"avg":33.199356,"sd":39.04137,"marketCap":11048417811},"quantilePoints":[{"date":"2020-08-21","current":87.719084,"twenty":14.813662,"median":19.570486,"eighty":28.081529,"marketCap":3289465651},{"date":"2020-08-28","current":90.040104,"twenty":14.83771,"median":19.594842,"eighty":28.170784,"marketCap":3376503903},{"date":"2020-09-04","current":88.260655,"twenty":14.871894,"median":19.605519,"eighty":28.267865,"marketCap":3309774577},{"date":"2020-09-11","current":84.237554,"twenty":14.936445,"median":19.626415,"eighty":28.310525,"marketCap":3158908274},{"date":"2020-09-18","current":81.978428,"twenty":15.011846,"median":19.656053,"eighty":28.373051,"marketCap":3074191042},{"date":"2020-09-25","current":76.779343,"twenty":15.041272,"median":19.669528,"eighty":28.409968,"marketCap":2879225359},{"date":"2020-10-02","current":76.965025,"twenty":15.066218,"median":19.682881,"eighty":28.47471,"marketCap":2886188419},{"date":"2020-10-09","current":80.137085,"twenty":15.081973,"median":19.70422,"eighty":28.560476,"marketCap":3005140696},{"date":"2020-10-16","current":84.253027,"twenty":15.124703,"median":19.713849,"eighty":28.62779,"marketCap":3159488529},{"date":"2020-10-23","current":85.320697,"twenty":15.162424,"median":19.729877,"eighty":28.703268,"marketCap":3199526125},{"date":"2020-10-30","current":136.527006,"twenty":15.223621,"median":19.752233,"eighty":28.737446,"marketCap":2948983334},{"date":"2020-11-06","current":142.122596,"twenty":15.260409,"median":19.772138,"eighty":28.792366,"marketCap":3069848070},{"date":"2020-11-13","current":165.258207,"twenty":15.260409,"median":19.790516,"eighty":28.85843,"marketCap":3569577265},{"date":"2020-11-20","current":177.390952,"twenty":15.260409,"median":19.802914,"eighty":28.931965,"marketCap":3831644553},{"date":"2020-11-27","current":191.003299,"twenty":15.260409,"median":19.824132,"eighty":28.993533,"marketCap":4125671266},{"date":"2020-12-04","current":198.293707,"twenty":15.260409,"median":19.834923,"eighty":29.072788,"marketCap":4283144070},{"date":"2020-12-11","current":204.884666,"twenty":15.277405,"median":19.845593,"eighty":29.204431,"marketCap":4425508783},{"date":"2020-12-18","current":208.059087,"twenty":15.319129,"median":19.880269,"eighty":29.408025,"marketCap":4494076277},{"date":"2020-12-24","current":206.848503,"twenty":15.339718,"median":19.900532,"eighty":29.534806,"marketCap":4467927656},{"date":"2020-12-31","current":208.919947,"twenty":15.365764,"median":19.915811,"eighty":29.796111,"marketCap":4512670852},{"date":"2021-01-08","current":218.147289,"twenty":15.386249,"median":19.927575,"eighty":30.133245,"marketCap":4711981450},{"date":"2021-01-15","current":217.178822,"twenty":15.463133,"median":19.955186,"eighty":30.348098,"marketCap":4691062553},{"date":"2021-01-22","current":216.990509,"twenty":15.518993,"median":19.983043,"eighty":30.612845,"marketCap":4686994990},{"date":"2021-01-29","current":24.296226,"twenty":15.546124,"median":20.000911,"eighty":30.612845,"marketCap":4397616921},{"date":"2021-02-05","current":26.22567,"twenty":15.604175,"median":20.036867,"eighty":30.612845,"marketCap":4746846277},{"date":"2021-02-12","current":26.752174,"twenty":15.64869,"median":20.047071,"eighty":30.612845,"marketCap":4842143473},{"date":"2021-02-19","current":27.198418,"twenty":15.679949,"median":20.069656,"eighty":30.612845,"marketCap":4922913657},{"date":"2021-02-26","current":26.948508,"twenty":15.757032,"median":20.101665,"eighty":30.612845,"marketCap":4877680001},{"date":"2021-03-05","current":28.764142,"twenty":16.078184,"median":20.131636,"eighty":30.613864,"marketCap":5206309765},{"date":"2021-03-12","current":30.119103,"twenty":16.146147,"median":20.17181,"eighty":30.613864,"marketCap":5451557630},{"date":"2021-03-19","current":30.222173,"twenty":16.146147,"median":20.191936,"eighty":30.619304,"marketCap":5470213373},{"date":"2021-03-26","current":30.595804,"twenty":16.155113,"median":20.208951,"eighty":30.618171,"marketCap":5537840438},{"date":"2021-04-01","current":30.605466,"twenty":16.155113,"median":20.23058,"eighty":30.618171,"marketCap":5539589413},{"date":"2021-04-09","current":30.682769,"twenty":16.146147,"median":20.256725,"eighty":30.624072,"marketCap":5553581220},{"date":"2021-04-16","current":30.421872,"twenty":16.146147,"median":20.279169,"eighty":30.659957,"marketCap":5506358873},{"date":"2021-04-23","current":30.705316,"twenty":16.146147,"median":20.301119,"eighty":30.68362,"marketCap":5557662164},{"date":"2021-04-30","current":30.296255,"twenty":16.155113,"median":20.344302,"eighty":30.707893,"marketCap":5483622187},{"date":"2021-05-07","current":25.569844,"twenty":16.155113,"median":20.376409,"eighty":30.707893,"marketCap":5794126672},{"date":"2021-05-14","current":25.399722,"twenty":16.199938,"median":20.42789,"eighty":30.707893,"marketCap":5755577038},{"date":"2021-05-21","current":24.309395,"twenty":16.338001,"median":20.491036,"eighty":30.707893,"marketCap":5508508935},{"date":"2021-05-28","current":24.613553,"twenty":16.445582,"median":20.602521,"eighty":30.707893,"marketCap":5577431007},{"date":"2021-06-04","current":24.257843,"twenty":16.445582,"median":20.635149,"eighty":30.707893,"marketCap":5496827228},{"date":"2021-06-11","current":23.729434,"twenty":16.445582,"median":20.724193,"eighty":30.707893,"marketCap":5377089732},{"date":"2021-06-18","current":22.296285,"twenty":16.445582,"median":20.784488,"eighty":30.707893,"marketCap":5052338277},{"date":"2021-06-25","current":23.739744,"twenty":16.445582,"median":20.844829,"eighty":30.707893,"marketCap":5379426073},{"date":"2021-07-02","current":24.116075,"twenty":16.637435,"median":20.901381,"eighty":30.707893,"marketCap":5464702534},{"date":"2021-07-09","current":24.409922,"twenty":17.169936,"median":20.986777,"eighty":30.707893,"marketCap":5531288264},{"date":"2021-07-16","current":23.314439,"twenty":17.256001,"median":21.022105,"eighty":30.707893,"marketCap":5283051990},{"date":"2021-07-23","current":23.799029,"twenty":17.256001,"median":21.108637,"eighty":30.707893,"marketCap":5392860036},{"date":"2021-07-30","current":16.221256,"twenty":15.768581,"median":21.108637,"eighty":30.707893,"marketCap":5679061858},{"date":"2021-08-06","current":16.529487,"twenty":15.768581,"median":21.108637,"eighty":30.707893,"marketCap":5786973465},{"date":"2021-08-13","current":17.085494,"twenty":15.768581,"median":21.108637,"eighty":30.707893,"marketCap":5981631539},{"date":"2021-08-20","current":16.514415,"twenty":15.768581,"median":21.108637,"eighty":30.707893,"marketCap":5781696589},{"date":"2021-08-27","current":17.391968,"twenty":15.768581,"median":21.108637,"eighty":30.707893,"marketCap":6088928007},{"date":"2021-09-03","current":16.290002,"twenty":15.768581,"median":21.108637,"eighty":30.707893,"marketCap":5703129776},{"date":"2021-09-10","current":15.723947,"twenty":15.757032,"median":21.108637,"eighty":30.707893,"marketCap":5504953785},{"date":"2021-09-17","current":15.378954,"twenty":15.742757,"median":21.108637,"eighty":30.707893,"marketCap":5384171968},{"date":"2021-09-24","current":15.594993,"twenty":15.679949,"median":21.108637,"eighty":30.707893,"marketCap":5459807184},{"date":"2021-10-01","current":16.263207,"twenty":15.679949,"median":21.108637,"eighty":30.707893,"marketCap":5693748664},{"date":"2021-10-08","current":16.043818,"twenty":15.679949,"median":21.108637,"eighty":30.707893,"marketCap":5616940810},{"date":"2021-10-15","current":15.605042,"twenty":15.643409,"median":21.108637,"eighty":30.707893,"marketCap":5463325101},{"date":"2021-10-22","current":15.794285,"twenty":15.639757,"median":21.108637,"eighty":30.707893,"marketCap":5529579204},{"date":"2021-10-29","current":14.76593,"twenty":15.597281,"median":21.108637,"eighty":30.707893,"marketCap":6055507796},{"date":"2021-11-05","current":15.208034,"twenty":15.546124,"median":21.108637,"eighty":30.707893,"marketCap":6236814727},{"date":"2021-11-12","current":15.298251,"twenty":15.518993,"median":21.108637,"eighty":30.707893,"marketCap":6273812781},{"date":"2021-11-19","current":14.851461,"twenty":15.463133,"median":21.108637,"eighty":30.707893,"marketCap":6090584325},{"date":"2021-11-26","current":14.333071,"twenty":15.432575,"median":21.108637,"eighty":30.707893,"marketCap":5877992336},{"date":"2021-12-03","current":14.039507,"twenty":15.386249,"median":21.108637,"eighty":30.707893,"marketCap":5757601844},{"date":"2021-12-10","current":14.812797,"twenty":15.373275,"median":21.108637,"eighty":30.707893,"marketCap":6074728017},{"date":"2021-12-17","current":13.748807,"twenty":15.338429,"median":21.108637,"eighty":30.707893,"marketCap":5638385894},{"date":"2021-12-23","current":14.274358,"twenty":15.317813,"median":21.108637,"eighty":30.707893,"marketCap":5853914237},{"date":"2021-12-31","current":14.567922,"twenty":15.293897,"median":21.108637,"eighty":30.707893,"marketCap":5974304729},{"date":"2022-01-07","current":15.013279,"twenty":15.255263,"median":21.086933,"eighty":30.706604,"marketCap":6156945913},{"date":"2022-01-14","current":15.296819,"twenty":15.234158,"median":21.086933,"eighty":30.706604,"marketCap":6273225510},{"date":"2022-01-21","current":14.26147,"twenty":15.159469,"median":21.086933,"eighty":30.706604,"marketCap":5848628801},{"date":"2022-01-28","current":13.473236,"twenty":15.141331,"median":21.086933,"eighty":30.706604,"marketCap":5866246922},{"date":"2022-02-04","current":13.791554,"twenty":15.108005,"median":21.086933,"eighty":30.706604,"marketCap":6004842805},{"date":"2022-02-11","current":13.714672,"twenty":15.072408,"median":21.086933,"eighty":30.706604,"marketCap":5971368375},{"date":"2022-02-18","current":13.760532,"twenty":15.03684,"median":21.086933,"eighty":30.706604,"marketCap":5991335579},{"date":"2022-02-25","current":13.698487,"twenty":15.01748,"median":21.086933,"eighty":30.706604,"marketCap":5964321127},{"date":"2022-03-04","current":13.275413,"twenty":15.000697,"median":21.086933,"eighty":30.706604,"marketCap":5780114910},{"date":"2022-03-11","current":13.404745,"twenty":14.95296,"median":21.086933,"eighty":30.706604,"marketCap":5836425811},{"date":"2022-03-18","current":14.316596,"twenty":14.909849,"median":21.086933,"eighty":30.706604,"marketCap":6233446103},{"date":"2022-03-25","current":14.323128,"twenty":14.844637,"median":21.086933,"eighty":30.706604,"marketCap":6236290088},{"date":"2022-04-01","current":14.200329,"twenty":14.811668,"median":21.086933,"eighty":30.706604,"marketCap":6182823172},{"date":"2022-04-08","current":13.370779,"twenty":14.787157,"median":21.086933,"eighty":30.706604,"marketCap":5821637090},{"date":"2022-04-14","current":13.605352,"twenty":14.765711,"median":21.086933,"eighty":30.706604,"marketCap":5923770233},{"date":"2022-04-22","current":13.520383,"twenty":14.746344,"median":21.086933,"eighty":30.706604,"marketCap":5886774696},{"date":"2022-04-29","current":12.486253,"twenty":14.722676,"median":21.019089,"eighty":30.706604,"marketCap":5394061408},{"date":"2022-05-06","current":12.456696,"twenty":14.697062,"median":20.987955,"eighty":30.706604,"marketCap":5381292864},{"date":"2022-05-13","current":11.781959,"twenty":14.669658,"median":20.987955,"eighty":30.706604,"marketCap":5089806167},{"date":"2022-05-20","current":11.653499,"twenty":14.65307,"median":20.987955,"eighty":30.706604,"marketCap":5034311584},{"date":"2022-05-27","current":12.38533,"twenty":14.632214,"median":20.987955,"eighty":30.706604,"marketCap":5350462540},{"date":"2022-06-03","current":12.325642,"twenty":14.611294,"median":20.987955,"eighty":30.706604,"marketCap":5324677178},{"date":"2022-06-10","current":11.976595,"twenty":14.57907,"median":20.987955,"eighty":30.706604,"marketCap":5173888868},{"date":"2022-06-17","current":10.930751,"twenty":14.551074,"median":20.987955,"eighty":30.706604,"marketCap":4722084488},{"date":"2022-06-24","current":11.496493,"twenty":14.512301,"median":20.989133,"eighty":30.707893,"marketCap":4966484872},{"date":"2022-07-01","current":11.448483,"twenty":14.475592,"median":20.989133,"eighty":30.707893,"marketCap":4945744472},{"date":"2022-07-08","current":11.682046,"twenty":14.446312,"median":20.989133,"eighty":30.707893,"marketCap":5046643714},{"date":"2022-07-15","current":11.634035,"twenty":14.405366,"median":20.901381,"eighty":30.707893,"marketCap":5025903314},{"date":"2022-07-22","current":12.2945,"twenty":14.378471,"median":20.826627,"eighty":30.707893,"marketCap":5311223946},{"date":"2022-07-29","current":10.048078,"twenty":14.354753,"median":20.788925,"eighty":30.707893,"marketCap":5545534406},{"date":"2022-08-05","current":10.145269,"twenty":14.322523,"median":20.788925,"eighty":30.707893,"marketCap":5599173918},{"date":"2022-08-12","current":10.721601,"twenty":14.301896,"median":20.788925,"eighty":30.707893,"marketCap":5917251426},{"date":"2022-08-19","current":10.554902,"twenty":14.25908,"median":20.788925,"eighty":30.707893,"marketCap":5825250171},{"date":"2022-08-26","current":9.974504,"twenty":14.187553,"median":20.788925,"eighty":30.707893,"marketCap":5504928730},{"date":"2022-09-02","current":9.465258,"twenty":14.135304,"median":20.788925,"eighty":30.707893,"marketCap":5223876117},{"date":"2022-09-09","current":9.759015,"twenty":14.102002,"median":20.788925,"eighty":30.707893,"marketCap":5386000279},{"date":"2022-09-16","current":9.233506,"twenty":14.059394,"median":20.788925,"eighty":30.707893,"marketCap":5095971933},{"date":"2022-09-23","current":8.782199,"twenty":14.031264,"median":20.788925,"eighty":30.707893,"marketCap":4846895366},{"date":"2022-09-30","current":8.898075,"twenty":13.970918,"median":20.788925,"eighty":30.707893,"marketCap":4910847458},{"date":"2022-10-07","current":9.505917,"twenty":13.919195,"median":20.788925,"eighty":30.707893,"marketCap":5246315447},{"date":"2022-10-14","current":9.625859,"twenty":13.853034,"median":20.788925,"eighty":30.707893,"marketCap":5312511472},{"date":"2022-10-21","current":10.108676,"twenty":13.814554,"median":20.788925,"eighty":30.707893,"marketCap":5578978520},{"date":"2022-10-28","current":14.974971,"twenty":13.814554,"median":20.751188,"eighty":30.707893,"marketCap":5630588980},{"date":"2022-11-04","current":15.463609,"twenty":13.814554,"median":20.751188,"eighty":30.707893,"marketCap":5814316860},{"date":"2022-11-11","current":15.563653,"twenty":13.814554,"median":20.751188,"eighty":30.707893,"marketCap":5851933626},{"date":"2022-11-18","current":15.647273,"twenty":13.814554,"median":20.751188,"eighty":30.707893,"marketCap":5883374505},{"date":"2022-11-25","current":16.044465,"twenty":13.814554,"median":20.751188,"eighty":30.707893,"marketCap":6032718681},{"date":"2022-12-02","current":15.78614,"twenty":13.814554,"median":20.751188,"eighty":30.707893,"marketCap":5935588822},{"date":"2022-12-09","current":14.866328,"twenty":13.814554,"median":20.751188,"eighty":30.707893,"marketCap":5589739152},{"date":"2022-12-16","current":14.373571,"twenty":13.814554,"median":20.751188,"eighty":30.707893,"marketCap":5404462543},{"date":"2022-12-23","current":14.855875,"twenty":13.814554,"median":20.344302,"eighty":30.707893,"marketCap":5585809042},{"date":"2022-12-30","current":14.999223,"twenty":13.814554,"median":19.765377,"eighty":30.707893,"marketCap":5639707692},{"date":"2023-01-06","current":15.569626,"twenty":13.814554,"median":19.464991,"eighty":30.682769,"marketCap":5854179403},{"date":"2023-01-13","current":16.083288,"twenty":13.814554,"median":19.115452,"eighty":30.607602,"marketCap":6047316232},{"date":"2023-01-20","current":16.159441,"twenty":13.814554,"median":18.427296,"eighty":30.461812,"marketCap":6075949889},{"date":"2023-01-27","current":15.870494,"twenty":13.814554,"median":17.1977,"eighty":30.416074,"marketCap":6365655133},{"date":"2023-02-03","current":16.700552,"twenty":13.814554,"median":17.005108,"eighty":30.370928,"marketCap":6698591585},{"date":"2023-02-10","current":16.651561,"twenty":13.814554,"median":16.756543,"eighty":30.27693,"marketCap":6678941035},{"date":"2023-02-17","current":16.851727,"twenty":13.814554,"median":16.756543,"eighty":30.179893,"marketCap":6759227566},{"date":"2023-02-24","current":16.526982,"twenty":13.814554,"median":16.695284,"eighty":30.105575,"marketCap":6628972495},{"date":"2023-03-03","current":17.355997,"twenty":13.814554,"median":16.651561,"eighty":29.955493,"marketCap":6961490255},{"date":"2023-03-10","current":15.566371,"twenty":13.814554,"median":16.584753,"eighty":29.755722,"marketCap":6243671220},{"date":"2023-03-17","current":15.480547,"twenty":13.814554,"median":16.531531,"eighty":29.517526,"marketCap":6209247509},{"date":"2023-03-24","current":14.869936,"twenty":13.814554,"median":16.458394,"eighty":29.346477,"marketCap":5964331266},{"date":"2023-03-31","current":15.968755,"twenty":13.81764,"median":16.370108,"eighty":29.233228,"marketCap":6405067639},{"date":"2023-04-06","current":16.098193,"twenty":13.814554,"median":16.263207,"eighty":29.165128,"marketCap":6456985367},{"date":"2023-04-13","current":16.098193,"twenty":13.811468,"median":16.213847,"eighty":29.047766,"marketCap":6456985367},{"date":"2023-04-21","current":11.256514,"twenty":13.795287,"median":16.167243,"eighty":28.957812,"marketCap":4514987632},{"date":"2023-04-28","current":10.547063,"twenty":13.769342,"median":16.098193,"eighty":28.929603,"marketCap":4230427133},{"date":"2023-05-05","current":9.97455,"twenty":13.75401,"median":16.098193,"eighty":28.929603,"marketCap":4000792069},{"date":"2023-05-12","current":10.85153,"twenty":13.72131,"median":16.043818,"eighty":28.869244,"marketCap":4360144650},{"date":"2023-05-19","current":10.855892,"twenty":13.715462,"median":15.968755,"eighty":28.809081,"marketCap":4361897590},{"date":"2023-05-26","current":10.676792,"twenty":13.696628,"median":15.930768,"eighty":28.764729,"marketCap":4289934926},{"date":"2023-06-02","current":10.354878,"twenty":13.660339,"median":15.878021,"eighty":28.764729,"marketCap":4160590154},{"date":"2023-06-09","current":11.276849,"twenty":13.620925,"median":15.820484,"eighty":28.752181,"marketCap":4531038118},{"date":"2023-06-16","current":11.224609,"twenty":13.575222,"median":15.789127,"eighty":28.740612,"marketCap":4510047958},{"date":"2023-06-23","current":11.398273,"twenty":13.554976,"median":15.774827,"eighty":28.742195,"marketCap":4579826058},{"date":"2023-06-30","current":12.275063,"twenty":13.534076,"median":15.748467,"eighty":28.744691,"marketCap":4932120371},{"date":"2023-07-07","current":12.273651,"twenty":13.517745,"median":15.73232,"eighty":28.744691,"marketCap":4931553069},{"date":"2023-07-14","current":12.851119,"twenty":13.480736,"median":15.69546,"eighty":28.744691,"marketCap":5163579436},{"date":"2023-07-21","current":13.091142,"twenty":13.444539,"median":15.669077,"eighty":28.744691,"marketCap":5260020713},{"date":"2023-07-28","current":28.047249,"twenty":13.437725,"median":15.657467,"eighty":28.744691,"marketCap":5306539447},{"date":"2023-08-04","current":27.615476,"twenty":13.437725,"median":15.657467,"eighty":28.744691,"marketCap":5224848012},{"date":"2023-08-11","current":26.895854,"twenty":13.437725,"median":15.657467,"eighty":28.744691,"marketCap":5088695621},{"date":"2023-08-18","current":25.936359,"twenty":13.437725,"median":15.657467,"eighty":28.744691,"marketCap":4907159099},{"date":"2023-08-25","current":26.047301,"twenty":13.437725,"median":15.657467,"eighty":28.735863,"marketCap":4928149259},{"date":"2023-09-01","current":27.32163,"twenty":13.437725,"median":15.657467,"eighty":28.633914,"marketCap":5169252452},{"date":"2023-09-08","current":25.936359,"twenty":13.437725,"median":15.657467,"eighty":28.427306,"marketCap":4907159099},{"date":"2023-09-15","current":26.131256,"twenty":13.437725,"median":15.657467,"eighty":28.310023,"marketCap":4944033705},{"date":"2023-09-22","current":25.732466,"twenty":13.437725,"median":15.657467,"eighty":28.103852,"marketCap":4868582588},{"date":"2023-09-29","current":26.778916,"twenty":13.437725,"median":15.657467,"eighty":28.040876,"marketCap":5066570857},{"date":"2023-10-06","current":25.921367,"twenty":13.437725,"median":15.657467,"eighty":27.952179,"marketCap":4904322591},{"date":"2023-10-13","current":26.404113,"twenty":13.437725,"median":15.657467,"eighty":27.770815,"marketCap":4995658153},{"date":"2023-10-20","current":25.186753,"twenty":13.437725,"median":15.657467,"eighty":27.598634,"marketCap":4765333692},{"date":"2023-10-27","current":17.482305,"twenty":13.425722,"median":15.649693,"eighty":27.611266,"marketCap":5309375955},{"date":"2023-11-03","current":18.634591,"twenty":13.425722,"median":15.649693,"eighty":27.611266,"marketCap":5659325216},{"date":"2023-11-10","current":18.896496,"twenty":13.425722,"median":15.649693,"eighty":27.611266,"marketCap":5738865978},{"date":"2023-11-17","current":19.770139,"twenty":13.421721,"median":15.647273,"eighty":27.615476,"marketCap":6004191234},{"date":"2023-11-24","current":20.363168,"twenty":13.421721,"median":15.647273,"eighty":27.615476,"marketCap":6184294245},{"date":"2023-12-01","current":19.770139,"twenty":13.421721,"median":15.647273,"eighty":27.615476,"marketCap":6004191234},{"date":"2023-12-08","current":19.455852,"twenty":13.425722,"median":15.649693,"eighty":27.611266,"marketCap":5908742320},{"date":"2023-12-15","current":20.419291,"twenty":13.425722,"median":15.649693,"eighty":27.611266,"marketCap":6201338694},{"date":"2023-12-22","current":21.33222,"twenty":13.425722,"median":15.649693,"eighty":27.611266,"marketCap":6478595064},{"date":"2023-12-29","current":22.136644,"twenty":13.421721,"median":15.647273,"eighty":27.615476,"marketCap":6722898833},{"date":"2024-01-05","current":21.592254,"twenty":13.419632,"median":15.645413,"eighty":27.624048,"marketCap":6557567678},{"date":"2024-01-12","current":21.081538,"twenty":13.419632,"median":15.645413,"eighty":27.624048,"marketCap":6402463192},{"date":"2024-01-19","current":21.749398,"twenty":13.417543,"median":15.643553,"eighty":27.632621,"marketCap":6605292135},{"date":"2024-01-26","current":21.257389,"twenty":13.419632,"median":15.645413,"eighty":27.624048,"marketCap":6455869132},{"date":"2024-02-02","current":28.058844,"twenty":13.419632,"median":15.669077,"eighty":27.669555,"marketCap":7180258215},{"date":"2024-02-09","current":28.169854,"twenty":13.419632,"median":15.704121,"eighty":27.796495,"marketCap":7208665630},{"date":"2024-02-16","current":27.308418,"twenty":13.419632,"median":15.733099,"eighty":27.825797,"marketCap":6988224090},{"date":"2024-02-23","current":27.148564,"twenty":13.419632,"median":15.755466,"eighty":27.825797,"marketCap":6947317412},{"date":"2024-03-01","current":27.092062,"twenty":13.441726,"median":15.777181,"eighty":27.812943,"marketCap":6932858665},{"date":"2024-03-08","current":29.888075,"twenty":13.445242,"median":15.789127,"eighty":27.963376,"marketCap":7648358285},{"date":"2024-03-15","current":28.812755,"twenty":13.445242,"median":15.827779,"eighty":28.043716,"marketCap":7373184090},{"date":"2024-03-22","current":30.106708,"twenty":13.445242,"median":15.896443,"eighty":28.076477,"marketCap":7704306565},{"date":"2024-03-28","current":30.093322,"twenty":13.445242,"median":15.930965,"eighty":28.169854,"marketCap":7700881160},{"date":"2024-04-05","current":30.22941,"twenty":13.444539,"median":15.993577,"eighty":28.367293,"marketCap":7735706111},{"date":"2024-04-12","current":30.521665,"twenty":13.444539,"median":16.063876,"eighty":28.550678,"marketCap":7810494118},{"date":"2024-04-19","current":28.866298,"twenty":13.444539,"median":16.098193,"eighty":28.738359,"marketCap":7386885709},{"date":"2024-04-26","current":38.231767,"twenty":13.445242,"median":16.102434,"eighty":28.817217,"marketCap":8219830006},{"date":"2024-05-03","current":37.612546,"twenty":13.445242,"median":16.172772,"eighty":28.907655,"marketCap":8086697428},{"date":"2024-05-10","current":38.354269,"twenty":13.445242,"median":16.221256,"eighty":29.130483,"marketCap":8246167924},{"date":"2024-05-17","current":38.702534,"twenty":13.445242,"median":16.290002,"eighty":29.281518,"marketCap":8321044752},{"date":"2024-05-24","current":38.854069,"twenty":13.445242,"median":16.385606,"eighty":29.401797,"marketCap":8353624746},{"date":"2024-05-31","current":39.239552,"twenty":13.454387,"median":16.514415,"eighty":29.631749,"marketCap":8436503678},{"date":"2024-06-07","current":37.902323,"twenty":13.473236,"median":16.552178,"eighty":29.829217,"marketCap":8148999521},{"date":"2024-06-14","current":38.593535,"twenty":13.469601,"median":16.648062,"eighty":29.922236,"marketCap":8297610020},{"date":"2024-06-21","current":37.928908,"twenty":13.465967,"median":16.735546,"eighty":30.031355,"marketCap":8154715310},{"date":"2024-06-28","current":38.468585,"twenty":13.455063,"median":16.771844,"eighty":30.093322,"marketCap":8270745814},{"date":"2024-07-05","current":38.447317,"twenty":13.455063,"median":16.814111,"eighty":30.119103,"marketCap":8266173184},{"date":"2024-07-12","current":38.896605,"twenty":13.455063,"median":16.946902,"eighty":30.175867,"marketCap":8362770008},{"date":"2024-07-15","current":39.090676,"twenty":13.455063,"median":17.002596,"eighty":30.222173,"marketCap":8404495263},{"date":"2024-08-02","current":36.716509,"twenty":13.443132,"median":17.163621,"eighty":30.257604,"marketCap":8848678588},{"date":"2024-08-09","current":34.544426,"twenty":13.474636,"median":17.391968,"eighty":30.380644,"marketCap":8325206621},{"date":"2024-08-16","current":35.878536,"twenty":13.516412,"median":18.180924,"eighty":30.441623,"marketCap":8646727108},{"date":"2024-08-23","current":35.80732,"twenty":13.536427,"median":18.692584,"eighty":30.507515,"marketCap":8629564092},{"date":"2024-08-30","current":37.015615,"twenty":13.564424,"median":19.093862,"eighty":30.613864,"marketCap":8920763252},{"date":"2024-09-06","current":35.370529,"twenty":13.617967,"median":19.465206,"eighty":30.68362,"marketCap":8524297599},{"date":"2024-09-13","current":35.593672,"twenty":13.654447,"median":19.770139,"eighty":30.724008,"marketCap":8578075046},{"date":"2024-09-20","current":36.657162,"twenty":13.697093,"median":19.955344,"eighty":30.811628,"marketCap":8834376075},{"date":"2024-09-27","current":37.647062,"twenty":13.718449,"median":20.170481,"eighty":31.202877,"marketCap":9072941988},{"date":"2024-10-04","current":37.063092,"twenty":13.754547,"median":20.419291,"eighty":33.022546,"marketCap":8932205262},{"date":"2024-10-11","current":36.813837,"twenty":13.782708,"median":20.788925,"eighty":33.919642,"marketCap":8872134709},{"date":"2024-10-18","current":38.748534,"twenty":13.844231,"median":21.132049,"eighty":34.498848,"marketCap":9338396624},{"date":"2024-10-25","current":35.731356,"twenty":13.972834,"median":21.270485,"eighty":35.063709,"marketCap":8611256876},{"date":"2024-10-31","current":35.156674,"twenty":14.041756,"median":21.392084,"eighty":35.155808,"marketCap":9249721045},{"date":"2024-11-08","current":37.821894,"twenty":14.04673,"median":21.716135,"eighty":35.381924,"marketCap":9950940184},{"date":"2024-11-15","current":37.830595,"twenty":14.04673,"median":21.871932,"eighty":35.703819,"marketCap":9953229467},{"date":"2024-11-22","current":39.842745,"twenty":14.04673,"median":22.117001,"eighty":35.842453,"marketCap":10482626124},{"date":"2024-11-29","current":39.607813,"twenty":14.04673,"median":22.252579,"eighty":36.21515,"marketCap":10420815487},{"date":"2024-12-06","current":38.322212,"twenty":14.04673,"median":22.415358,"eighty":36.508084,"marketCap":10082573948},{"date":"2024-12-13","current":36.138213,"twenty":14.04673,"median":22.859046,"eighty":36.698326,"marketCap":9507963955},{"date":"2024-12-20","current":33.179809,"twenty":14.04673,"median":23.30284,"eighty":36.698326,"marketCap":8729607789},{"date":"2024-12-27","current":34.026,"twenty":14.04673,"median":23.434298,"eighty":36.698326,"marketCap":8952240545},{"date":"2025-01-03","current":32.842638,"twenty":14.04673,"median":23.518071,"eighty":36.698326,"marketCap":8640898079},{"date":"2025-01-10","current":33.425618,"twenty":14.045235,"median":23.729434,"eighty":36.704639,"marketCap":8794280029},{"date":"2025-01-17","current":33.814996,"twenty":14.045235,"median":23.80934,"eighty":36.704639,"marketCap":8896725436},{"date":"2025-01-24","current":35.437768,"twenty":14.045235,"median":23.953686,"eighty":36.704639,"marketCap":9323676686},{"date":"2025-01-31","current":33.333263,"twenty":14.045235,"median":23.956263,"eighty":36.531348,"marketCap":9823312666},{"date":"2025-02-07","current":33.556598,"twenty":14.045235,"median":23.956263,"eighty":36.222746,"marketCap":9889129548},{"date":"2025-02-14","current":32.746766,"twenty":14.045235,"median":23.956263,"eighty":35.878536,"marketCap":9650471812},{"date":"2025-02-21","current":33.306075,"twenty":14.045235,"median":23.956263,"eighty":35.814441,"marketCap":9815300176},{"date":"2025-02-28","current":31.197014,"twenty":14.045235,"median":23.956263,"eighty":35.764062,"marketCap":9193759885},{"date":"2025-03-07","current":29.524826,"twenty":14.045214,"median":23.954974,"eighty":35.772714,"marketCap":8700966306},{"date":"2025-03-14","current":29.365117,"twenty":14.045214,"median":23.967817,"eighty":35.772714,"marketCap":8653899927},{"date":"2025-03-21","current":29.877642,"twenty":14.045214,"median":24.116075,"eighty":35.772714,"marketCap":8804941148},{"date":"2025-03-28","current":30.412112,"twenty":14.045214,"median":24.170205,"eighty":35.772714,"marketCap":8962449399},{"date":"2025-04-04","current":28.45369,"twenty":14.045214,"median":24.30281,"eighty":35.772714,"marketCap":8385302378},{"date":"2025-04-11","current":27.414009,"twenty":14.045235,"median":24.43312,"eighty":35.764062,"marketCap":8078908592},{"date":"2025-04-17","current":27.614923,"twenty":14.045235,"median":24.592932,"eighty":35.764062,"marketCap":8138117897},{"date":"2025-04-25","current":29.14811,"twenty":14.045214,"median":24.78754,"eighty":35.772714,"marketCap":8589948135},{"date":"2025-05-02","current":27.818973,"twenty":14.045214,"median":24.78754,"eighty":35.772714,"marketCap":9374993854},{"date":"2025-05-09","current":28.96729,"twenty":14.045214,"median":24.78754,"eighty":35.772714,"marketCap":9761976856},{"date":"2025-05-16","current":30.05077,"twenty":14.045214,"median":24.915132,"eighty":35.772714,"marketCap":10127109406},{"date":"2025-05-23","current":29.127679,"twenty":14.045214,"median":24.915132,"eighty":35.772714,"marketCap":9816027974},{"date":"2025-05-30","current":29.564484,"twenty":14.045214,"median":24.915132,"eighty":35.772714,"marketCap":9963231018},{"date":"2025-06-06","current":29.840899,"twenty":14.045214,"median":24.915132,"eighty":35.772714,"marketCap":10056382944},{"date":"2025-06-13","current":31.878181,"twenty":14.045214,"median":24.915132,"eighty":35.772714,"marketCap":10742947140},{"date":"2025-06-20","current":30.439799,"twenty":14.045193,"median":24.891934,"eighty":35.781365,"marketCap":10258212117},{"date":"2025-06-27","current":32.052221,"twenty":14.045193,"median":24.891934,"eighty":35.781365,"marketCap":10801598353},{"date":"2025-07-03","current":32.958248,"twenty":14.045193,"median":24.891934,"eighty":35.781365,"marketCap":11106929667},{"date":"2025-07-11","current":31.879888,"twenty":14.045193,"median":24.891934,"eighty":35.781365,"marketCap":10743522152},{"date":"2025-07-18","current":32.303042,"twenty":14.045193,"median":24.891934,"eighty":35.781365,"marketCap":10886125101},{"date":"2025-07-25","current":32.277448,"twenty":14.045193,"median":24.891934,"eighty":35.781365,"marketCap":10877499923},{"date":"2025-08-01","current":32.02372,"twenty":14.045193,"median":24.891934,"eighty":35.443157,"marketCap":11265944866},{"date":"2025-08-08","current":31.84542,"twenty":14.045193,"median":24.891934,"eighty":35.35024,"marketCap":11203218811},{"date":"2025-08-15","current":31.240181,"twenty":14.045193,"median":24.891934,"eighty":35.144538,"marketCap":10990295503},{"date":"2025-08-20","current":31.405395,"twenty":14.045193,"median":24.891934,"eighty":34.721243,"marketCap":11048417811}],"updateTime":1755768542787},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CR\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2521260564","title":"CR Construction Group Holdings Full Year 2024 Earnings: EPS: HK$0.11 (vs HK$0.14 in FY 2023)","url":"https://stock-news.laohu8.com/highlight/detail?id=2521260564","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521260564?lang=en_us&edition=fundamental","pubTime":"2025-03-22 08:06","pubTimestamp":1742601960,"startTime":"0","endTime":"0","summary":"CR Construction Group Holdings ( HKG:1582 ) Full Year 2024 Results Key Financial Results Revenue: HK$6.07b (up 11% from...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/3041000-choice1-main-header/1585186744280","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3041000-choice1-main-header/1585186744280"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/capital-goods/hkg-1582/cr-construction-group-holdings-shares/news/cr-construction-group-holdings-full-year-2024-earnings-eps-h","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["01582","CR"],"gpt_icon":0},{"id":"2521200024","title":"BioInvent’s anti-TNFR2 antibody BI-1808 showcased at the 16th Annual T-Cell Lymphoma Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2521200024","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521200024?lang=en_us&edition=fundamental","pubTime":"2025-03-21 15:20","pubTimestamp":1742541600,"startTime":"0","endTime":"0","summary":"BioInvent International AB  , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that one of the company's lead program; BI-1808 as monotherapy in Cutaneous T Cell Lymphoma  will be presented at the 16th Annual T-Cell Lymphoma Forum held March 20-22, 2025 in La Jolla, California.The data, previously disclosed in a press release in September 2024, will be featured in a poster presentation highlighting the early efficacy of BI-1808 monotherapy in the ongoing Phase 2a dose expansion study in CTCL. So far three partial responses  and one stable disease  out of four evaluable patients have been reported. The Company anticipates reporting additional data from the study in mid-2025.BI-1808, a first-in-class anti-TNFR2 antibody, was recently granted Orphan Drug Designation by the U.S. Food and Drug Administration  for the treatment of TCL.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioinvent-anti-tnfr2-antibody-bi-072000423.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["FET","BOVNF","CR","BK4139","BK4213","BK4161","SD","BK4179","PR"],"gpt_icon":0},{"id":"2521151496","title":"Press Release: SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2521151496","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521151496?lang=en_us&edition=fundamental","pubTime":"2025-03-21 04:05","pubTimestamp":1742501100,"startTime":"0","endTime":"0","summary":"-- Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S  in Acute Myeloid Leukemia  with Next and Final Analysis Planned Upon Reaching 80 Events, Anticipated in 2025 --. -- Reported Positive Overall Survival and Overall Response Rate Data from the Ongoing Phase 2 Trial of SLS009  in r/r AML -- Full Data and FDA Regulatory Path Feedback Expected in 1H 2025 --. Announced Positive Outcome of Interim Analysis for Phase 3 REGAL Trial of GPS in AML: The interim futility, efficacy, and safety analysis was designed to assess whether the therap","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","ASH","BK4202","R","LU2463526074.USD","BK4022","BK4585","BK4181","BK4588","LU2355687059.USD","ORR","BK4161","CR","ODD","INN","BK4232","BK4097","BK4139","LU1699723380.USD","BK4183","LU0985320562.USD","SLS","BK4218","NCI","BK4107","BK4109","ALL","LU1571399168.USD","OS","BK4213","PR"],"gpt_icon":0},{"id":"2521493824","title":"Aptevo Therapeutics Says Two Additional Patients In Early-Stage Leukemia Trial Achieve Remission Within 30 Days of Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2521493824","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521493824?lang=en_us&edition=fundamental","pubTime":"2025-03-21 02:26","pubTimestamp":1742495195,"startTime":"0","endTime":"0","summary":"On Thursday, Aptevo Therapeutics  announced two additional frontline Acute Myeloid Leukemia  patients have achieved remission within 30 days of treatment in the RAINIER dose optimization trial of mipletamig in combination with standard of care for patients unfit for intensive chemotherapy.9 of 10 frontline patients across two trials achieved remission when receiving the triplet combination of mipletamig + venetoclax + azacitidine .Notably, no cytokine release syndrome  has been reported in the RAINIER trial to date.Together with the addition of these interim Cohort 2 results, mipletamig has achieved a compelling overall remission rate of 90% among frontline patients, outperforming the doublet remission rate from a venetoclax + azacitidine-only study of 66%.In December 2024, Aptevo Therapeutics announced that 100% of patients achieved remission within 30 days in Cohort 1 of the RAINIER frontline acute myeloid leukemia  Phase 1b trial, including two patients who experienced complete remi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aptevo-therapeutics-says-two-additional-182635823.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4161","SSI","IE00B7SZL793.SGD","IE00B66KJ199.SGD","BK4139","APVO","IE00B19Z4B17.USD","CR","LU2065731478.USD","CRS","BK4006","IE0031619046.USD"],"gpt_icon":0},{"id":"2520452538","title":"RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2520452538","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520452538?lang=en_us&edition=fundamental","pubTime":"2025-03-20 20:35","pubTimestamp":1742474100,"startTime":"0","endTime":"0","summary":"Across two trials, 9 of 10 frontline AML patients achieved remission when treated with mipletamig in combination with the standard of care. Triplet Combination with mipletamig continues to outperform doublet combination benchmark. No Cytokine Release Syndrome  has been observed in the RAINIER trial to date. The data builds on previously reported favorable outcomes from RAINIER's Cohort 1 and the completed dose expansion trial where 100% of frontline patients achieved remission. Together with the addition of these interim Cohort 2 results, mipletamig has achieved a compelling overall remission rate of 90% among frontline patients. This outperforms the doublet remission* rate from a venetoclax + azacitidine only study, of 66%. Additionally, the frontline patient triplet therapy CR rate of 70% outperforms the CR rate from a venetoclax + azacitidine only study of 36% .Thus far, all RAINIER patients who achieved remission remain in remission.Two patients achieved remission withing 30 days o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rainier-trial-data-two-additional-123500697.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0031619046.USD","LU2065731478.USD","BK4161","IE00B66KJ199.SGD","BK4006","BK4139","CRS","IE00B19Z4B17.USD","IE00B7SZL793.SGD","CR","APVO"],"gpt_icon":0},{"id":"2520455465","title":"CR Construction Group Announces Final Dividend for 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2520455465","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520455465?lang=en_us&edition=fundamental","pubTime":"2025-03-20 20:13","pubTimestamp":1742472791,"startTime":"0","endTime":"0","summary":"The latest update is out from CR Construction Group Holdings Limited ( ($HK:1582) ). CR Construction Group Holdings Limited has announced a final o...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cr-construction-group-announces-final-dividend-for-2024?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cr-construction-group-announces-final-dividend-for-2024?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CR","BK4161"],"gpt_icon":0},{"id":"2520107816","title":"BioInvent Receives FDA Orphan Drug Designation for BI-1808 for the Treatment of T-cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2520107816","media":"ACCESS Newswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520107816?lang=en_us&edition=fundamental","pubTime":"2025-03-20 15:20","pubTimestamp":1742455200,"startTime":"0","endTime":"0","summary":"LUND, SE / ACCESS Newswire / March 20, 2025 / BioInvent International AB  , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that the U.S. Food and Drug Administration  has granted Orphan Drug Designation  for BI-1808, a first-in-class anti-TNFR2 antibody for the treatment of T-cell Lymphoma .\"We are excited to receive the FDA's Orphan Drug Designation for the treatment of TCL. This designation along with the recently announced positive Phase 2a data in CTCL reinforces our continued progress and commitment to developing BI-1808 as a potential novel class of immunomodulatory agents for TCL\", said Martin Welschof, Chief Executive Officer of BioInvent. \"We look forward to working closely with the regulatory agencies to accelerate the development of BI-1808 and bring this innovative treatment to patients who are in great need of new treatment options.\". About the Phase 1/2a studyDur","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioinvent-receives-fda-orphan-drug-072000957.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ODD","PR","BOVNF","BK4213","BK4139","BK4183","SD","BK4161","CR"],"gpt_icon":0},{"id":"2520474631","title":"CR Double-Crane Pharmaceutical 2024 Profit Down 3%; Shares Decline 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2520474631","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520474631?lang=en_us&edition=fundamental","pubTime":"2025-03-20 10:23","pubTimestamp":1742437401,"startTime":"0","endTime":"0","summary":"China Resources Double-Crane Pharmaceutical  posted 2024 net profit attributable to shareholders of 1.63 billion yuan, down 2.6% from 1.67 billion yuan the previous year.Earnings per share declined to 1.5838 yuan from 1.6306 yuan, according to a filing with the Shanghai bourse.The company's revenue inched down 0.9% year over year to 11.2 billion yuan from 11.3 billion yuan.The board declared a cash distribution of 0.371 yuan per share for 2024.Shares of the company were down 3% in recent trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0010","BK0185","BK0175","BK0239","BK0188","CR","600062","BK4161","BK0028"],"gpt_icon":0},{"id":"2520927182","title":"Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical Data in 2H:2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2520927182","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520927182?lang=en_us&edition=fundamental","pubTime":"2025-03-19 20:30","pubTimestamp":1742387400,"startTime":"0","endTime":"0","summary":"-  Actinium to highlight 3 separate multi-billion-dollar market opportunities for Actimab-A and Iomab-ACT in myeloid malignancies, solid tumors and cell & gene therapy conditioning. -  Clinical proof of concept data expected in 2H:2025 from Actimab-A combination with blockbuster immunotherapies KEYTRUDA and OPDIVO in solid tumor indications. - Actimab-A expanded into frontline AML in triplet combination with Venetoclax and ASTX-727, Taiho Oncology's hypomethylating agent, under NCI CRADA with initial clinical data expected by year-end 2025. - Iomab-ACT commercial CAR-T trial to initiate patient enrollment with clinical proof of concept data expected in 2H:2025; Iomab-ACT sickle cell disease trial expected to initiate in 1H:2025. Actimab-A as a mutation agnostic, backbone therapy for myeloid malignancies including AML and myelodysplastic syndromes  across multiple treatment settings. Sandesh Seth, Actinium's Chairman and CEO, said, \"We have made significant progress across our pipeline ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-host-investor-kol-123000877.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-host-investor-kol-123000877.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NCI","HST","ACT","BK4181","BK4585","BK4139","BK4202","KOL","BK4218","ATNM","BK4161","HMA","CR","BK4588"],"gpt_icon":0},{"id":"2520902634","title":"CR Double-Crane Reports 2024 Financial Results with Dividend Proposal","url":"https://stock-news.laohu8.com/highlight/detail?id=2520902634","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520902634?lang=en_us&edition=fundamental","pubTime":"2025-03-19 19:08","pubTimestamp":1742382519,"startTime":"0","endTime":"0","summary":"China Resources Pharmaceutical Group Ltd. ( ($HK:3320) ) has issued an announcement. CR Double-Crane, a subsidiary of China Resources Pharmaceutica...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cr-double-crane-reports-2024-financial-results-with-dividend-proposal?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cr-double-crane-reports-2024-financial-results-with-dividend-proposal?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CR","BK4161"],"gpt_icon":0},{"id":"2520937540","title":"Kratos Defense begins building IPIF  in Crane, Indiana to support MACH-TB","url":"https://stock-news.laohu8.com/highlight/detail?id=2520937540","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520937540?lang=en_us&edition=fundamental","pubTime":"2025-03-19 04:25","pubTimestamp":1742329509,"startTime":"0","endTime":"0","summary":"Kratos Defense (KTOS) & Security Solutions announced the groundbreaking of Kratos’ Hypersonic System Indiana Payload Integration Facility IPIF in C...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kratos-defense-begins-building-ipif-in-crane-indiana-to-support-mach-tb?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kratos-defense-begins-building-ipif-in-crane-indiana-to-support-mach-tb?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CR","BK4187","BK4603","KTOS","BK4161"],"gpt_icon":0},{"id":"2520155931","title":"Press Release: INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2520155931","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520155931?lang=en_us&edition=fundamental","pubTime":"2025-03-19 04:05","pubTimestamp":1742328300,"startTime":"0","endTime":"0","summary":"-- Significant progress toward submitting a biologics license application.  for INO-3107 as a potential treatment for recurrent respiratory. -- Resolved previously announced manufacturing issue concerning the. single-use array component of the CELLECTRA device and completed. -- On track to begin rolling submission of BLA in mid-2025 and to. request priority review with goal of completing the submission in. the second half of 2025 and receiving acceptance of the submission. in surgery of 50% or greater in year 2; data to be included in BLA. \"INOVIO's recent progress puts us on the cusp of achieving several long-term goals for our DNA medicines, most importantly the submission of our first BLA and potential transition to a commercial-stage company, \" said Dr. Jacqueline Shea, INOVIO's President and Chief Executive Officer. \"By resolving the previously announced device array component issue, we are back on track to submitting our first BLA for INO-3107 to the FDA. We anticipate starting o","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","IE00BSNM7G36.USD","BK4585","LU2237438978.USD","BK4588","BK4022","BK4149","BK4023","BK4232","LU0868494708.USD","BK4597","LU1064131342.USD","LU1988902786.USD","LU2106854487.HKD","BK4583","CAT","BK4161","INO","LU2023250504.SGD","CR","IE00BD6J9T35.USD","BK4568","LU2264538146.SGD","DV","LU0942090050.USD","LU1974910355.USD","BK4139","BK4516","LU0868494617.USD","BK4539","LU1917777945.USD","R","BK4520"],"gpt_icon":0},{"id":"2520784126","title":"Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA® and OPDIVO®","url":"https://stock-news.laohu8.com/highlight/detail?id=2520784126","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520784126?lang=en_us&edition=fundamental","pubTime":"2025-03-18 20:00","pubTimestamp":1742299200,"startTime":"0","endTime":"0","summary":"- Trials are designed to demonstrate whether the addition of Actimab-A to either KEYTRUDA or OPDIVO can result in improved patient outcomes. - MDSCs – Myeloid Derived Suppressor Cells in the tumor microenvironment are believed to reduce effectiveness of PD-1 inhibitors like KEYTRUDA and OPDIVO. - Trials supported by preclinical data showing Actimab-A can selectively target and deplete MDSCs which express CD33. - Clinical proof of concept data expected in 2025 could potentially open up a multi-billion-dollar market opportunity for Actimab-A as a combination therapy with PD-1 inhibitors in multiple solid tumors. Actimab-A is Actinium's lead radiotherapeutic that delivers Actinium-225, a potent alpha-emitter radioisotope payload that can produce lethal double strand DNA br","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-announces-clinical-trial-120000511.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-announces-clinical-trial-120000511.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2023250504.SGD","LU1941712348.USD","LU1699723380.USD","BK4023","SG9999002224.SGD","SG9999015358.SGD","LU1941712264.USD","LU1169589451.USD","IE0009355771.USD","LU0965509101.SGD","LU1116320901.HKD","LU1057294990.SGD","LU1929549753.HKD","LU1093756325.SGD","SG9999013999.USD","HMA","LU1989772840.SGD","ATNM","BK4202","SG9999015341.SGD","LU1974910355.USD","LU1116320737.USD","LU1989772923.USD","LU1934455277.USD","CR","IE00BJT1NW94.SGD","LU0320765646.SGD","LU2023250843.SGD","SGXZ57979304.SGD","NCI","IE0002141913.USD","IE00B2B36J28.USD","SG9999014542.SGD","PD","IE00BFTCPJ56.SGD","SG9999001176.SGD","LU0985320562.USD","IE00B4R5TH58.HKD","LU2324357040.USD","MRK","LU0965509283.SGD","SG9999002232.USD","IE00BJJMRZ35.SGD","LU1037948897.HKD","LU1989771016.USD","LU0289739699.SGD","LU1983299246.USD","LU0266013472.USD","LU1037948541.HKD","LU1934455194.USD"],"gpt_icon":0},{"id":"2520650806","title":"Crane Company (CR): Among the Best Reddit Stocks to Invest In","url":"https://stock-news.laohu8.com/highlight/detail?id=2520650806","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520650806?lang=en_us&edition=fundamental","pubTime":"2025-03-18 00:59","pubTimestamp":1742230784,"startTime":"0","endTime":"0","summary":"We recently published a list of 11 Best Reddit Stocks to Invest In. In this article, we are going to take a look at where Crane Company  stands against other best Reddit stocks to invest in.In finance, cognitive biases tend to affect investor decision-making, says Austin Barbosa, CFA, senior analyst in Client Portfolio Management at iA Global Asset Management. Among such biases, confirmation bias is particularly pervasive. This bias refers to the inclination to favour information aligning with pre-existing beliefs while, at the same time, also discounting contradictory evidence. Confirmation bias gets exacerbated by echo chambers on social media platforms, in which algorithm-fueled content personalization results in an environment reinforcing investors’ views.Austin Barbosa, CFA believes thatplatforms such as X and Reddit also provide significant value to stay informed. While X provides access to breaking news and expert opinions, Reddit enables in-depth discussions and diverse communi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/crane-company-cr-among-best-165944976.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2360107168.USD","LU2290526834.HKD","RDDT","LU1861215975.USD","LU1861220033.SGD","BK4077","BK4547","CR","BK4161"],"gpt_icon":1},{"id":"2520443526","title":"Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2520443526","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520443526?lang=en_us&edition=fundamental","pubTime":"2025-03-17 20:50","pubTimestamp":1742215800,"startTime":"0","endTime":"0","summary":"- Median Overall Survival of 18.4 months with Actimab-A + CLAG-M in patients with relapsed or refractory AML who received 1 or 2 lines of prior therapy. - Mutation agnostic potential of Actimab-A demonstrated by high rates of Complete Remissions and Measurable Residual Disease Negativity in patients with high-risk features including TP53 mutations and prior Venetoclax treatment. - Actimab-A + CLAG-M combination yielded deep and clinically meaningful responses with expected and manageable safety profile supporting planned pivotal Phase 2/3 trial. 52% of patients in the Actimab-A +CLAG-M trial had TP53 mutations, 56% had prior allogeneic stem cell transplant and 56% of patients had prior Venetoclax therapy. Actimab-A + CLAG-M produced high rates of measurable residual disease negativity  including 75% across all patients, 83.3% in patients with a TP53 mutation and 100% in patients with prior Venetoclax therapy. Dr. Sameem Abedin, Associate Professor of Medicine at the Medical College of ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-announces-publication-actimab-125000660.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-announces-publication-actimab-125000660.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MCW","NCI","OS","BK4539","BK4139","BK4202","BK4535","HMA","ATNM","BK4097","BK4192","CR","BK4161"],"gpt_icon":0},{"id":"2520522383","title":"INAB: Introducing INB-600, A γδ T Cell Engager Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2520522383","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520522383?lang=en_us&edition=fundamental","pubTime":"2025-03-17 17:31","pubTimestamp":1742203860,"startTime":"0","endTime":"0","summary":"Following the announcement of its new γδ T cell engager platform INB-600, IN8bio, Inc.  reported 2024 financial and operational results on March 14th, 2025. Other corporate achievements since the third quarter report in mid-November include a stakeholder update on glioblastoma multiforme  and acute myeloid leukemia  efforts and presentations at multiple investor and scientific conferences.The most important information shared related to the INB-100 patients. Trial data was updated by about four months from early August 2024 to January 17th, 2025 and were presented at the Transplantation & Cellular Therapy  Meetings in February. All of the acute myeloid leukemia  patients across both original and expansion cohorts remain in complete remission , with a median follow-up of 20.1 months. All of the AML patients achieved one year of both progression free survival  and overall survival .General & administrative expenses were $12.6 million, falling 6.5% from $13.5 million. The decrease was pri","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inab-introducing-inb-600-t-093100072.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4097","IE00B66KJ199.SGD","IE00B19Z4B17.USD","INAB","CR","BK4006","INB","BK4211","BK4139","OS","BK4195","BK4161","IE0031619046.USD","LU2065731478.USD","CRS","PFS","IE00B7SZL793.SGD","BK4539"],"gpt_icon":0},{"id":"2519808851","title":"Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2519808851","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519808851?lang=en_us&edition=fundamental","pubTime":"2025-03-14 18:59","pubTimestamp":1741949940,"startTime":"0","endTime":"0","summary":"In the TRANSCEND FL trial, 97.1% of patients responded to Breyanzi, with 94.2% of patients achieving complete response*. Breyanzi demonstrated sustained clinical benefit, with 75.7% of patients still in response at 18 months, and a consistent safety profile with no new safety signals observed. PRINCETON, N.J., March 14, 2025----Bristol Myers Squibb  today announced that the European Commission  has granted approval to Breyanzi , a CD19-directed chimeric antigen receptor  T cell therapy, for the treatment of adult patients with relapsed or refractory follicular lymphoma  after two or more lines of systemic therapy.This expanded approval is applicable to all European Union  member states as well as the European Economic Area  countries Iceland, Norway and Liechtenstein.** Breyanzi is also approved in the EU for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma , high grade B-cell lymphoma , primary mediastinal large B-cell lymphoma  and FL grade 3B","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bristol-myers-squibb-receives-approval-105900919.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0456855351.SGD","BK4585","BK4528","EEA","CAR","LU0868494617.USD","LU0061475181.USD","BK4534","LU0096364046.USD","LU0237698245.USD","LU1430594728.SGD","LU1323610961.USD","CR","MYE","LU0225771236.USD","LU2133065610.SGD","IE00BFTCPJ56.SGD","UK","LU0306806265.USD","HSCT","LU0882574055.USD","LU2125154778.USD","LU2242646821.SGD","LU2360032135.SGD","CRS","LU1670711040.USD","BK4201","BK4230","BMY","IE0031619046.USD","IE00BJJMRZ35.SGD","IE00BFXG1179.USD","BK4588","LU2242652126.USD","LU1718418525.SGD","EC","LU2125154935.USD","IE00BSNM7G36.USD","LU1261432733.SGD","BK4094","LU1585245621.USD","LU1093756325.SGD","FL","BK4156","LU2065731478.USD","BK4205","LU0114720955.EUR","IE00B66KJ199.SGD","LU1032466523.USD"],"gpt_icon":0},{"id":"2519985816","title":"3 Industrials Stocks Walking a Fine Line","url":"https://stock-news.laohu8.com/highlight/detail?id=2519985816","media":"StockStory","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519985816?lang=en_us&edition=fundamental","pubTime":"2025-03-13 21:02","pubTimestamp":1741870933,"startTime":"0","endTime":"0","summary":"Even if they go mostly unnoticed, industrial businesses are the backbone of our country. Still, their generally high capital requirements expose them to the ups and downs of economic cycles, and the market seems to be baking in a prolonged downturn as the industry has shed 6% over the past six months. This drop was disappointing since the S&P 500 held steady.Some companies can grow regardless of the economic backdrop, but the odds aren’t great for the ones we’re analyzing today. Keeping that in mind, here are three industrials stocks we’re swiping left on.Founded in 1952, Distribution Solutions  provides supply chain solutions and distributes industrial, safety, and maintenance products to various industries.Founded in 1895, Albany  is a global textiles and materials processing company, specializing in machine clothing for paper mills and engineered composite structures for aerospace and other industries.Annual revenue growth of 3.1% over the last five years was below our standards for","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-industrials-stocks-walking-fine-130213388.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CR","BK4161","AIN","BK4104","DSGR"],"gpt_icon":0},{"id":"2519005605","title":"CR Sanjiu Logs 18% Boost in 2024 Profit","url":"https://stock-news.laohu8.com/highlight/detail?id=2519005605","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519005605?lang=en_us&edition=fundamental","pubTime":"2025-03-13 15:15","pubTimestamp":1741850114,"startTime":"0","endTime":"0","summary":"China Resources Sanjiu Medical & Pharmaceutical  recorded an 18% rise in attributable profit for 2024 to 3.37 billion yuan from 2.85 billion yuan a year prior, a Wednesday filing by parent China Resources Pharmaceutical Group  with the Hong Kong bourse said.Earnings per share were 2.63 yuan in the year, up from 2.23 yuan in the last fiscal year.The drug company's revenue rose by 12% to 27.6 billion yuan in the period from 24.7 billion yuan a year prior.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CR","BK0239","BK4161","BK0183","BK0028","03320","BK0175","BK0010","BK0196","BK0060","BK1191","BK1570","BK0012","BK0188","000999","BK0185"],"gpt_icon":0},{"id":"2518056478","title":"The Agfa-Gevaert Group in 2024: strong performance from growth engines offsets decline in traditional film markets - regulated information","url":"https://stock-news.laohu8.com/highlight/detail?id=2518056478","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518056478?lang=en_us&edition=fundamental","pubTime":"2025-03-12 14:45","pubTimestamp":1741761900,"startTime":"0","endTime":"0","summary":"Regulated information March 12, 2025 - 7:45 a.m. CETThe Agfa-Gevaert Group in 2024: strong performance from growth engines offsets decline in traditional film markets. The Agfa-Gevaert Group posted strong Q4 revenue growth, profitability and free cash flow, with record performances of its growth engines. The strong year-end resulted in significant full year revenue growth and a strong profitability step up in Digital Printing Solutions, Green Hydrogen Solutions and Direct Radiography, as well as a significant increase in order intake in HealthCare IT, with a high share of cloud-based and net new customer contracts. This was counterbalanced by an accelerated market decline for the traditional film activities. The savings program to align the costs base to the evolution of the traditional film markets is on track.32% increase in order intake in FY 2024 versus the year before, of which 27% cloud-related contracts and 33% net new customer contracts","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/agfa-gevaert-group-2024-strong-064500308.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["EBIT","CR","BK4205","BK4528","USA","AFGVY","BK4233","UK","AFGVF","BK4167","BK4161"],"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":6,"totalSize":161,"code":"91000000","status":"200"}]}}